Fedratinib Hydrochloride and Venclexta Starting Pack
Determining the interaction of Fedratinib Hydrochloride and Venclexta Starting Pack and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of the isoenzyme. In 11 previously treated non-Hodgkin's lymphoma patients, venetoclax peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.3- and 6.4-fold, respectively, when coadministered with 400 mg once daily for 7 days of ketoconazole, a potent CYP450 3A4 inhibitor that also inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia. MANAGEMENT: Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the CYP450 3A4 inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor. References "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL. Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of the isoenzyme. In 11 previously treated non-Hodgkin's lymphoma patients, venetoclax peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.3- and 6.4-fold, respectively, when coadministered with 400 mg once daily for 7 days of ketoconazole, a potent CYP450 3A4 inhibitor that also inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia.
MANAGEMENT: Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the CYP450 3A4 inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.
- "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: fedratinib
Brand name: Inrebic
Synonyms: Fedratinib
Generic Name: venetoclax
Brand name: Venclexta, Venclexta Starting Pack
Synonyms: Venclexta
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fedratinib Hydrochloride-Venetoclax
- Fedratinib Hydrochloride-Venipuncture CPI
- Fedratinib Hydrochloride-Venipuncture PX1
- Fedratinib Hydrochloride-Venlafaxine
- Fedratinib Hydrochloride-Venlafaxine ER
- Fedratinib Hydrochloride-Venlafaxine ER Capsules
- Venclexta Starting Pack-Feiba
- Venclexta Starting Pack-Feiba NF
- Venclexta Starting Pack-Feiba VH Immuno
- Venclexta Starting Pack-Feiba-VH
- Venclexta Starting Pack-Felbamate
- Venclexta Starting Pack-Felbamate Oral Suspension